ArticleSkin health and disease2025
Three cases of chronic photodermatitis successfully treated with upadacitinib.
Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodermatoses represent a varied collection of skin disorders characterized by cutaneous reactions provoked by exposure to ultraviolet radiation. The disease mechanism is based on an immune-mediated delayed hypersensitivity reaction. Clinical presentation of patients with photodermatosis includes pigmentary changes, erythema and/or lichenification, with interindividual differences in lesion morphology and distribution. Most patients report associated symptoms of burning sensation and itchiness as their chief complaint, severely affecting their quality of life. Management of photodermatoses involves both preventive measures and medical management applying topical steroids and calcineurin inhibitors, or systemic immunosuppressives, with variable degree of success and adverse events. Here, we report three cases of chronic photodermatitis treated with upadacitinib, a selective Janus kinase 1 inhibitor, as monotherapy, which resulted in fast, significant and sustainable improvement of signs and symptoms, with a favourable safety and tolerability profile.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.